331 related articles for article (PubMed ID: 22753629)
1. The effect of duloxetine treatment on cognition in patients with fibromyalgia.
Mohs R; Mease P; Arnold LM; Wang F; Ahl J; Gaynor PJ; Wohlreich MM
Psychosom Med; 2012; 74(6):628-34. PubMed ID: 22753629
[TBL] [Abstract][Full Text] [Related]
2. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.
Arnold LM; Clauw D; Wang F; Ahl J; Gaynor PJ; Wohlreich MM
J Rheumatol; 2010 Dec; 37(12):2578-86. PubMed ID: 20843911
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.
Arnold LM; Zhang S; Pangallo BA
Clin J Pain; 2012; 28(9):775-81. PubMed ID: 22971669
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
5. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial.
Arnold LM; Wang F; Ahl J; Gaynor PJ; Wohlreich MM
Arthritis Res Ther; 2011 Jun; 13(3):R86. PubMed ID: 21668963
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial.
Upadhyaya HP; Arnold LM; Alaka K; Qiao M; Williams D; Mehta R
Pediatr Rheumatol Online J; 2019 May; 17(1):27. PubMed ID: 31138224
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients.
Murakami M; Osada K; Mizuno H; Ochiai T; Alev L; Nishioka K
Arthritis Res Ther; 2015 Aug; 17(1):224. PubMed ID: 26296539
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials.
Arnold LM; Pritchett YL; D'Souza DN; Kajdasz DK; Iyengar S; Wernicke JF
J Womens Health (Larchmt); 2007 Oct; 16(8):1145-56. PubMed ID: 17937567
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.
Arnold LM; Rosen A; Pritchett YL; D'Souza DN; Goldstein DJ; Iyengar S; Wernicke JF
Pain; 2005 Dec; 119(1-3):5-15. PubMed ID: 16298061
[TBL] [Abstract][Full Text] [Related]
11. Effect of duloxetine in patients with fibromyalgia: tiredness subgroups.
Bradley LA; Bennett R; Russell IJ; Wohlreich MM; Chappell AS; Wang F; D'Souza DN; Moldofsky H
Arthritis Res Ther; 2010; 12(4):R141. PubMed ID: 20630058
[TBL] [Abstract][Full Text] [Related]
12. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold LM; Gendreau RM; Palmer RH; Gendreau JF; Wang Y
Arthritis Rheum; 2010 Sep; 62(9):2745-56. PubMed ID: 20496365
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of duloxetine in patients with chronic low back pain.
Skljarevski V; Desaiah D; Liu-Seifert H; Zhang Q; Chappell AS; Detke MJ; Iyengar S; Atkinson JH; Backonja M
Spine (Phila Pa 1976); 2010 Jun; 35(13):E578-85. PubMed ID: 20461028
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE
J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
[TBL] [Abstract][Full Text] [Related]
18. Pain response profile of patients with fibromyalgia treated with duloxetine.
Bradley LA; Wohlreich MM; Wang F; Gaynor PJ; Robinson MJ; D'Souza DN; Mease PJ
Clin J Pain; 2010; 26(6):498-504. PubMed ID: 20551724
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of patient-rated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of duloxetine.
Bennett R; Russell IJ; Choy E; Spaeth M; Mease P; Kajdasz D; Walker D; Wang F; Chappell A
Clin Ther; 2012 Apr; 34(4):824-37. PubMed ID: 22421576
[TBL] [Abstract][Full Text] [Related]
20. Predictors of pain medication selection among patients diagnosed with fibromyalgia.
Boulanger L; Wu N; Chen SY; Nagar S; Fraser K; Bernauer MJ; Zhao Z; Zhao Y
Pain Pract; 2012 Apr; 12(4):266-75. PubMed ID: 21899718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]